Avidity Biosciences

    Approach: Antibody Oligonucleotide Conjugate

    Status: Preclinical

    Description of DM1 program on company website

    June 17, 2019 Patent Application

    September 14, 2019 Presentation at Myotonic conference (starts at 15:20)

    November 13, 2019 Article on Avidity's $100 million capital raise

    May 22, 2020 S-1 for IPO. States it plans to start a clinical trial of its myotonic dystrophy T1 drug, AOC 10001, by the end of 2021

    Sept. 2020 Presentation at Myotonic Dystrophy Foundation annual conference (starts at 1:19)